Citadel Advisors’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,563,611
| Closed | -$14.1M | – | 14354 |
|
|
2025
Q4 | $14.1M | Sell |
1,563,611
-316,378
| -17% | -$2.36M | ﹤0.01% | 2784 |
|
|
2025
Q3 | $5.85M | Buy |
1,879,989
+114,508
| +6% | +$303K | ﹤0.01% | 4073 |
|
|
2025
Q2 | $3.78M | Buy |
1,765,481
+372,143
| +27% | +$601K | ﹤0.01% | 4588 |
|
|
2025
Q1 | $1.6M | Sell |
1,393,338
-3,088,129
| -69% | -$5.3M | ﹤0.01% | 5963 |
|
|
2024
Q4 | $9.81M | Buy |
4,481,467
+26,457
| +0.6% | +$60K | ﹤0.01% | 3009 |
|
|
2024
Q3 | $9.71M | Sell |
4,455,010
-1,303,384
| -23% | -$3M | ﹤0.01% | 2939 |
|
|
2024
Q2 | $13.3M | Sell |
5,758,394
-132,498
| -2% | -$551K | ﹤0.01% | 2439 |
|
|
2024
Q1 | $31.8M | Buy |
5,890,892
+1,624,939
| +38% | +$7.43M | 0.01% | 1610 |
|
|
2023
Q4 | $10.5M | Buy |
4,265,953
+1,326,472
| +45% | +$12.6M | ﹤0.01% | 2770 |
|
|
2023
Q3 | $102M | Buy |
2,939,481
+152,349
| +5% | +$5.27M | 0.02% | 612 |
|
|
2023
Q2 | $91.4M | Sell |
2,787,132
-226,891
| -8% | -$7.82M | 0.02% | 663 |
|
|
2023
Q1 | $101M | Sell |
3,014,023
-753,320
| -20% | -$29.3M | 0.02% | 611 |
|
|
2022
Q4 | $124M | Buy |
3,767,343
+296,179
| +9% | +$8.77M | 0.03% | 541 |
|
|
2022
Q3 | $121M | Sell |
3,471,164
-420,164
| -11% | -$9.3M | 0.03% | 509 |
|
|
2022
Q2 | $47.6M | Sell |
3,891,328
-20,582
| -0.5% | -$308K | 0.01% | 1053 |
|
|
2022
Q1 | $51.4M | Buy |
3,911,910
+20,882
| +0.5% | +$279K | 0.01% | 1102 |
|
|
2021
Q4 | $74.7M | Buy |
+3,891,028
| New | +$73.7M | 0.02% | 869 |
|
Other funds holding VTYX
Citadel Advisors's VTYX Position: Q1 2026 in Review
Citadel Advisors sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,563,611 shares — an estimated $14.1M sold.
Citadel Advisors first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $124M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Citadel Advisors reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,563,611 Ventyx Biosciences shares in Q1 2026, an estimated $14.1M.
- Citadel Advisors first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Citadel Advisors's Ventyx Biosciences position peaked at $124M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.